M Gupta1, M Stenson2, M O'Byrne3, M J Maurer3, T Habermann2, J R Cerhan3, G W Weiner4, T E Witzig2. 1. Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester gupta.mamta@mayo.edu. 2. Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester. 3. Department of Health Sciences Research, Mayo Clinic, Rochester, USA. 4. Department of Internal Medicine, University of Iowa College of Medicine, Iowa City, USA.
Abstract
BACKGROUND: T-cell malignancies are heterogeneous in their clinical presentation and pathology, and have a poor prognosis. New biomarkers are needed to predict prognosis and to provide insights into signal pathways used by these cells. The goal of this study was to evaluate pretreatment serum cytokines in patients with newly diagnosed T-cell neoplasms and correlate with clinical outcome. PATIENTS AND METHODS: We evaluated 30 cytokines in pretreatment serum from 68 untreated patients and 14 normal controls. Significantly elevated cytokines were correlated with patterns of abnormalities, event-free survival (EFS) and overall survival (OS). RESULTS: Our data demonstrated significantly elevated levels (versus controls) of seven cytokines-epidermal growth factor (EGF), IL-6, IL-12, interferon gamma-induced protein (IP)-10, soluble interleukin (sIL)-2Rα, monokine induced by gamma interferon (MIG), and IL-1RA-in all T-cell neoplasms (P < 0.05). In the angioimmunoblastic subset, all seven cytokines except IP-10 and in the peripheral T-cell lymphoma (TCL)-not otherwise specified subset, only IP-10, sIL-2Rα, MIG, and IL-8 were statistically elevated compared with control. Of these, elevated cytokines all but EGF were predictive of an inferior EFS; IL-1RA, sIL-2Rα, and MIG predicted an inferior OS. In a multivariate analysis, sIL-2Rα [hazard ratio (HR) = 3.95; 95% confidence interval (CI) 1.61-8.38] and IL-1RA (HR = 3.28; 95% CI 1.47-7.29) levels remained independent predictors of inferior EFS. TCL cell lines secreted high levels of sIL-2Rα and expressed the IL-2Rα surface receptor. CONCLUSIONS: This report describes the cytokines relevant to prognosis in patients with untreated TCL and provides the rationale to include serum IL-1RA and sIL-2Rα as biomarkers in future trials. Inhibition of these cytokines may also be of therapeutic benefit.
BACKGROUND: T-cell malignancies are heterogeneous in their clinical presentation and pathology, and have a poor prognosis. New biomarkers are needed to predict prognosis and to provide insights into signal pathways used by these cells. The goal of this study was to evaluate pretreatment serum cytokines in patients with newly diagnosed T-cell neoplasms and correlate with clinical outcome. PATIENTS AND METHODS: We evaluated 30 cytokines in pretreatment serum from 68 untreated patients and 14 normal controls. Significantly elevated cytokines were correlated with patterns of abnormalities, event-free survival (EFS) and overall survival (OS). RESULTS: Our data demonstrated significantly elevated levels (versus controls) of seven cytokines-epidermal growth factor (EGF), IL-6, IL-12, interferon gamma-induced protein (IP)-10, soluble interleukin (sIL)-2Rα, monokine induced by gamma interferon (MIG), and IL-1RA-in all T-cell neoplasms (P < 0.05). In the angioimmunoblastic subset, all seven cytokines except IP-10 and in the peripheral T-cell lymphoma (TCL)-not otherwise specified subset, only IP-10, sIL-2Rα, MIG, and IL-8 were statistically elevated compared with control. Of these, elevated cytokines all but EGF were predictive of an inferior EFS; IL-1RA, sIL-2Rα, and MIG predicted an inferior OS. In a multivariate analysis, sIL-2Rα [hazard ratio (HR) = 3.95; 95% confidence interval (CI) 1.61-8.38] and IL-1RA (HR = 3.28; 95% CI 1.47-7.29) levels remained independent predictors of inferior EFS. TCL cell lines secreted high levels of sIL-2Rα and expressed the IL-2Rα surface receptor. CONCLUSIONS: This report describes the cytokines relevant to prognosis in patients with untreated TCL and provides the rationale to include serum IL-1RA and sIL-2Rα as biomarkers in future trials. Inhibition of these cytokines may also be of therapeutic benefit.
Authors: Stephen M Ansell; Anne J Novak; Steven Ziesmer; Tammy Price-Troska; Betsy LaPlant; Stacey R Dillon; Thomas E Witzig Journal: Am J Hematol Date: 2009-02 Impact factor: 10.047
Authors: E C Vonderheid; Q Zhang; S R Lessin; M Polansky; J T Abrams; R D Bigler; M A Wasik Journal: J Am Acad Dermatol Date: 1998-02 Impact factor: 11.527
Authors: H Ariizumi; B Saito; Y Uto; N Hattori; H Nakashima; K Yanagisawa; H Harada; H Mori; T Nakamaki Journal: Bone Marrow Transplant Date: 2014-10-27 Impact factor: 5.483
Authors: Filiberto Cedeno-Laurent; Rei Watanabe; Jessica E Teague; Thomas S Kupper; Rachael A Clark; Charles J Dimitroff Journal: Blood Date: 2012-03-01 Impact factor: 22.113
Authors: Sherine F Elsawa; Anne J Novak; Steven C Ziesmer; Luciana L Almada; Lucy S Hodge; Deanna M Grote; Thomas E Witzig; Martin E Fernandez-Zapico; Stephen M Ansell Journal: Blood Date: 2011-09-14 Impact factor: 22.113
Authors: Bridget Charbonneau; Matthew J Maurer; Stephen M Ansell; Susan L Slager; Zachary S Fredericksen; Steven C Ziesmer; William R Macon; Thomas M Habermann; Thomas E Witzig; Brian K Link; James R Cerhan; Anne J Novak Journal: Cytokine Date: 2012-09-23 Impact factor: 3.861
Authors: James R Cerhan; Brian K Link; Thomas M Habermann; Matthew J Maurer; Andrew L Feldman; Sergei I Syrbu; Carrie A Thompson; Umar Farooq; Anne J Novak; Susan L Slager; Cristine Allmer; Julianne J Lunde; William R Macon; David J Inwards; Patrick B Johnston; Ivana N M Micallef; Grzegorz S Nowakowski; Stephen M Ansell; Neil E Kay; George J Weiner; Thomas E Witzig Journal: Int J Epidemiol Date: 2017-12-01 Impact factor: 7.196
Authors: Rebecca L Boddicker; Gina L Razidlo; Surendra Dasari; Yu Zeng; Guangzhen Hu; Ryan A Knudson; Patricia T Greipp; Jaime I Davila; Sarah H Johnson; Julie C Porcher; James B Smadbeck; Bruce W Eckloff; Daniel D Billadeau; Paul J Kurtin; Mark A McNiven; Brian K Link; Stephen M Ansell; James R Cerhan; Yan W Asmann; George Vasmatzis; Andrew L Feldman Journal: Blood Date: 2016-06-13 Impact factor: 22.113
Authors: Tammy Price-Troska; Zhi-Zhang Yang; David Diller; Alexander Bayden; Mark Jarosinski; Joseph Audie; Stephen M Ansell Journal: Invest New Drugs Date: 2018-04-26 Impact factor: 3.850
Authors: Jing Jing Han; Megan O'byrne; Mary J Stenson; Matthew J Maurer; Linda E Wellik; Andrew L Feldman; Ellen D McPhail; Thomas E Witzig; Mamta Gupta Journal: Blood Cancer J Date: 2018-11-12 Impact factor: 11.037